Newsletter
Every new paper in this field, in your inbox.
Dedicated perioperative Advanced Practice Providers (APPs) substantially decrease readmissions by almost 50%, saving $900 per case. Financially self-sustaining with 113 to 139 annual cases, these APPs prove pivotal in optimizing outcomes, minimizing resource utilization, and cost savings for high-volume hepatopancreatobiliary centers.
Unraveling the mystery of early recurrence in hepatocellular carcinoma (HCC), researchers crafted a risk scoring system based on tumor morphology. Analyzing 124 patients, they pinpointed age, histological grade, AFP, and intratumoral hemorrhage as key factors. The scoring system accurately stratified patients into low and high-risk…
Researchers classified intrahepatic cholangiocarcinoma (ICC) into perihilar and peripheral subtypes, revealing distinctive features and survival outcomes. Among 1264 patients, 84.3% were ICC-peripheral, while 15.7% were ICC-perihilar. The perihilar subtype exhibited aggressive characteristics and poorer survival than the peripheral subtype. Interestingly, ICC-perihilar behaved akin to bile…
In a retrospective study spanning 2013 to 2022, researchers delved into healthcare-associated infections (HAIs) post-pancreatoduodenectomy (PD). Among 2632 patients, HAIs decreased over time, especially in open PD (OPD). Robotic PD (RPD) exhibited significantly fewer HAIs (5.8% vs. 9.6% in OPD). RPD correlated with reduced infections,…
In this cohort study on 438 patients with gallbladder polyps (GPs), the risk of gallbladder cancer was 0.7% for all polyps, escalating to 5.9% for those ≥10 mm. GP size emerged as the sole predictor of malignancy (p = 0.0001), with a 21 mm cutoff…
In the realm of surgical oncology, randomized controlled trials (RCTs) often face recruitment and standardization challenges. This study dives into hepatopancreatobiliary (HPB) cancer surgery, spotlighting the pivotal role of large databases. While RCTs provide crucial evidence, big data steps in where they fall short. Beyond…
In the epic battle against cholangiocarcinoma, researchers scoured the SEER database (1975-2020) for insights. Early-onset warriors (EOC), comprising 274 out of 4037 fighters, emerged with a distinct profile—often non-white, intrahepatic warriors. Despite facing a more advanced enemy at diagnosis, EOCs defied the odds. They opted…
When facing borderline resectable intrahepatic cholangiocarcinoma (ICC), inducing hypertrophy pre-resection is a game-changer. In this single-center study, researchers found that portal vein embolization (PVE) prepped the battleground without raising perioperative issues. Overall survival (OS) matched non-PVE cases, but additional risks (multifocal tumors, lymph node involvement)…
Unveiling liver regeneration intricacies, this study decodes Gata3 and Ramp2's role in hepatic-vascular revival post-surgery. These hepatocyte conductors fuel liver sinusoidal endothelial cell proliferation. Pedf and Vegfa, playing contrasting roles in endothelial migration, spice up the dance. Gata3 inhibitors emerge as potential superheroes against post-hepatectomy…
Delving into the ideal moment for post-pancreatic adenocarcinoma surgery chemotherapy, a simulated trial tracked 1491 patients. Noteworthy findings revealed a median survival of 29.9 months for late initiators (>4-8 weeks) versus 30.4 months for early starters (0-4 weeks). Encouragingly, delaying treatment up to 8 weeks…
